KR20240096847A - 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 - Google Patents
에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 Download PDFInfo
- Publication number
- KR20240096847A KR20240096847A KR1020247019305A KR20247019305A KR20240096847A KR 20240096847 A KR20240096847 A KR 20240096847A KR 1020247019305 A KR1020247019305 A KR 1020247019305A KR 20247019305 A KR20247019305 A KR 20247019305A KR 20240096847 A KR20240096847 A KR 20240096847A
- Authority
- KR
- South Korea
- Prior art keywords
- months
- ephedrine
- less
- composition
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 220
- 238000000034 method Methods 0.000 title abstract description 84
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 title description 303
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 title description 157
- 229960002179 ephedrine Drugs 0.000 title description 94
- 229960004842 ephedrine sulfate Drugs 0.000 abstract description 175
- MZNZKBJIWPGRID-UHFFFAOYSA-N diphenylphosphorylmethyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CP(C=1C=CC=CC=1)C1=CC=CC=C1 MZNZKBJIWPGRID-UHFFFAOYSA-N 0.000 abstract description 140
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 109
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 63
- 239000011780 sodium chloride Substances 0.000 description 55
- 238000003860 storage Methods 0.000 description 54
- 239000000243 solution Substances 0.000 description 47
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 45
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 37
- 239000012632 extractable Substances 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 239000008121 dextrose Substances 0.000 description 28
- 239000000825 pharmaceutical preparation Substances 0.000 description 28
- 239000012633 leachable Substances 0.000 description 25
- 239000003814 drug Substances 0.000 description 21
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 20
- 239000012535 impurity Substances 0.000 description 20
- 208000001953 Hypotension Diseases 0.000 description 18
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 18
- 229940127557 pharmaceutical product Drugs 0.000 description 18
- 239000000284 extract Substances 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 235000019445 benzyl alcohol Nutrition 0.000 description 15
- 229960004217 benzyl alcohol Drugs 0.000 description 15
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 15
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 14
- 238000011002 quantification Methods 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- -1 (-)-ephedrine) Chemical compound 0.000 description 12
- KWGRBVOPPLSCSI-PSASIEDQSA-N (1s,2r)-2-(methylamino)-1-phenylpropan-1-ol Chemical compound CN[C@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-PSASIEDQSA-N 0.000 description 12
- ZDHCZVWCTKTBRY-UHFFFAOYSA-N 12-hydroxylauric acid Chemical compound OCCCCCCCCCCCC(O)=O ZDHCZVWCTKTBRY-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 229940126534 drug product Drugs 0.000 description 11
- 239000011521 glass Substances 0.000 description 11
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- 230000036543 hypotension Effects 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000002738 chelating agent Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007951 isotonicity adjuster Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 5
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 5
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 5
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 5
- 208000021822 hypotensive Diseases 0.000 description 5
- 230000001077 hypotensive effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- WXZOXVVKILCOPG-UHFFFAOYSA-N bis(2-ethylhexyl) benzene-1,3-dicarboxylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC(C(=O)OCC(CC)CCCC)=C1 WXZOXVVKILCOPG-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920005556 chlorobutyl Polymers 0.000 description 4
- 238000013329 compounding Methods 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000005308 flint glass Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QNODIIQQMGDSEF-UHFFFAOYSA-N (1-hydroxycyclohexyl)-phenylmethanone Chemical compound C=1C=CC=CC=1C(=O)C1(O)CCCCC1 QNODIIQQMGDSEF-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical group OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000011213 bioburden testing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 208000012866 low blood pressure Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- ATCRIUVQKHMXSH-UHFFFAOYSA-N 2,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920002884 Laureth 4 Polymers 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- MGWAVDBGNNKXQV-UHFFFAOYSA-N diisobutyl phthalate Chemical compound CC(C)COC(=O)C1=CC=CC=C1C(=O)OCC(C)C MGWAVDBGNNKXQV-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940062711 laureth-9 Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012764 mineral filler Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 2
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- 239000012929 tonicity agent Substances 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- VFUUBTZHHMDNOP-WPRPVWTQSA-N [(1r,2s)-2-(methylamino)-1-phenylpropyl] hydrogen sulfate Chemical compound CN[C@@H](C)[C@H](OS(O)(=O)=O)C1=CC=CC=C1 VFUUBTZHHMDNOP-WPRPVWTQSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UEHLXXJAWYWUGI-UHFFFAOYSA-M nitromersol Chemical compound CC1=CC=C([N+]([O-])=O)C2=C1O[Hg]2 UEHLXXJAWYWUGI-UHFFFAOYSA-M 0.000 description 1
- 229940118238 nitromersol Drugs 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- VPCDQGACGWYTMC-UHFFFAOYSA-N nitrosyl chloride Chemical compound ClN=O VPCDQGACGWYTMC-UHFFFAOYSA-N 0.000 description 1
- 235000019392 nitrosyl chloride Nutrition 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- FPJQWFBQXIKMMP-UHFFFAOYSA-N phenyl nitrate Chemical compound [O-][N+](=O)OC1=CC=CC=C1 FPJQWFBQXIKMMP-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849125P | 2019-05-16 | 2019-05-16 | |
| US62/849,125 | 2019-05-16 | ||
| PCT/US2020/033310 WO2020232424A1 (en) | 2019-05-16 | 2020-05-16 | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
| KR1020217040545A KR102675027B1 (ko) | 2019-05-16 | 2020-05-16 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217040545A Division KR102675027B1 (ko) | 2019-05-16 | 2020-05-16 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240096847A true KR20240096847A (ko) | 2024-06-26 |
Family
ID=73230956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247019305A Pending KR20240096847A (ko) | 2019-05-16 | 2020-05-16 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 |
| KR1020217040545A Active KR102675027B1 (ko) | 2019-05-16 | 2020-05-16 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217040545A Active KR102675027B1 (ko) | 2019-05-16 | 2020-05-16 | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US11090278B2 (https=) |
| EP (1) | EP3968975A4 (https=) |
| JP (3) | JP2022532657A (https=) |
| KR (2) | KR20240096847A (https=) |
| CN (1) | CN113825500A (https=) |
| AU (1) | AU2020276619A1 (https=) |
| CA (1) | CA3140043A1 (https=) |
| IL (1) | IL288044A (https=) |
| MX (1) | MX2021013888A (https=) |
| WO (1) | WO2020232424A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241601A (zh) * | 2025-06-04 | 2025-07-04 | 成都苑东生物制药股份有限公司 | 盐酸麻黄碱注射液及其制剂工艺 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022532657A (ja) | 2019-05-16 | 2022-07-15 | ネクサス ファーマシューティカルズ， インコーポレイテッド | エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法 |
| US10869845B1 (en) | 2020-01-22 | 2020-12-22 | Nevakar Inc. | Ephedrine compositions and methods |
| US20230172840A1 (en) * | 2021-12-05 | 2023-06-08 | Fresenius Kabi Austria Gmbh | Ephedrine liquid formulations |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK339289D0 (da) | 1989-07-07 | 1989-07-07 | Dak Lab As | Farmaceutisk praeparat |
| US7149574B2 (en) * | 2003-06-09 | 2006-12-12 | Palo Alto Investors | Treatment of conditions through electrical modulation of the autonomic nervous system |
| FR2890316B1 (fr) | 2005-09-02 | 2007-10-05 | Aguettant Soc Par Actions Simp | Seringue destinee a etre remplie puis sterilisee par autoclavage a la vapeur. |
| FR2896168B1 (fr) | 2006-01-19 | 2008-10-17 | Aguettant Soc Par Actions Simp | Seringue hypodermique preremplie equipee d'un dispositif de bouchage |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| KR101906132B1 (ko) * | 2010-07-17 | 2018-10-10 | 메르크 파텐트 게엠베하 | 침투 및 작용의 증진 |
| FR2963237B1 (fr) | 2010-07-28 | 2013-05-17 | Aguettant Lab | Nouvelle composition pharmaceutique utile pour prevenir ou traiter l'hypotension arterielle peroperatoire chez l'etre humain |
| CA2828635C (en) * | 2011-03-04 | 2020-01-14 | Grunenthal Gmbh | Parenteral administration of tapentadol |
| FR2992222B1 (fr) | 2012-06-22 | 2015-06-19 | Aguettant Lab | Dispositif de protection destine a equiper un dispositif d’injection pourvu d’un embout de raccordement |
| US10092701B2 (en) * | 2014-05-19 | 2018-10-09 | Medicom Innovation Partner A/S | Medical cartridge comprising a one way valve |
| ES2770731T3 (es) * | 2014-08-28 | 2020-07-02 | Sun Pharmaceutical Ind Ltd | Forma de dosificación parenteral de norepinefrina |
| FR3053893B1 (fr) | 2016-07-13 | 2018-07-27 | Laboratoire Aguettant | Dispositif medical comportant un emballage et une seringue pre-remplie disposee dans l’emballage |
| CA3051467C (en) * | 2017-01-30 | 2022-11-29 | Nevakar, Inc | Norepinephrine compositions and methods therefor |
| WO2019177725A1 (en) | 2018-03-13 | 2019-09-19 | Nevakar Inc. | Prefilled syringe, compositions and methods |
| FR3084263B1 (fr) | 2018-07-27 | 2020-07-10 | Laboratoire Aguettant | Systeme d’administration comportant un dispositif d’administration et un dispositif de protection pourvu d’une membrane de fermeture |
| JP2022532657A (ja) | 2019-05-16 | 2022-07-15 | ネクサス ファーマシューティカルズ， インコーポレイテッド | エフェドリンまたはエフェドリン塩を含む組成物ならびにその組成物を作製する方法および使用する方法 |
| US10869845B1 (en) | 2020-01-22 | 2020-12-22 | Nevakar Inc. | Ephedrine compositions and methods |
-
2020
- 2020-05-16 JP JP2021568373A patent/JP2022532657A/ja active Pending
- 2020-05-16 MX MX2021013888A patent/MX2021013888A/es unknown
- 2020-05-16 US US16/876,020 patent/US11090278B2/en active Active
- 2020-05-16 CN CN202080036184.0A patent/CN113825500A/zh active Pending
- 2020-05-16 AU AU2020276619A patent/AU2020276619A1/en not_active Abandoned
- 2020-05-16 CA CA3140043A patent/CA3140043A1/en active Pending
- 2020-05-16 KR KR1020247019305A patent/KR20240096847A/ko active Pending
- 2020-05-16 KR KR1020217040545A patent/KR102675027B1/ko active Active
- 2020-05-16 EP EP20805983.2A patent/EP3968975A4/en active Pending
- 2020-05-16 WO PCT/US2020/033310 patent/WO2020232424A1/en not_active Ceased
-
2021
- 2021-07-21 US US17/381,770 patent/US11464752B2/en active Active
- 2021-09-02 US US17/465,697 patent/US11241400B2/en active Active
- 2021-11-11 IL IL288044A patent/IL288044A/en unknown
- 2021-12-20 US US17/556,904 patent/US11426369B2/en active Active
-
2022
- 2022-05-06 US US17/738,557 patent/US11478436B2/en active Active
- 2022-09-12 US US17/943,185 patent/US11571398B1/en active Active
- 2022-10-10 US US17/962,626 patent/US20230068187A1/en active Pending
-
2023
- 2023-05-15 JP JP2023079995A patent/JP2023091072A/ja not_active Withdrawn
-
2025
- 2025-02-21 JP JP2025026685A patent/JP2025071269A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120241601A (zh) * | 2025-06-04 | 2025-07-04 | 成都苑东生物制药股份有限公司 | 盐酸麻黄碱注射液及其制剂工艺 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11464752B2 (en) | 2022-10-11 |
| US20210353561A1 (en) | 2021-11-18 |
| US20210393552A1 (en) | 2021-12-23 |
| US11090278B2 (en) | 2021-08-17 |
| AU2020276619A1 (en) | 2021-12-16 |
| US11241400B2 (en) | 2022-02-08 |
| US11478436B2 (en) | 2022-10-25 |
| CN113825500A (zh) | 2021-12-21 |
| JP2025071269A (ja) | 2025-05-02 |
| WO2020232424A1 (en) | 2020-11-19 |
| US20200360309A1 (en) | 2020-11-19 |
| US20220265580A2 (en) | 2022-08-25 |
| US20230068187A1 (en) | 2023-03-02 |
| EP3968975A4 (en) | 2023-02-15 |
| JP2022532657A (ja) | 2022-07-15 |
| KR20220009985A (ko) | 2022-01-25 |
| EP3968975A1 (en) | 2022-03-23 |
| JP2023091072A (ja) | 2023-06-29 |
| US20220257539A1 (en) | 2022-08-18 |
| US11426369B2 (en) | 2022-08-30 |
| MX2021013888A (es) | 2022-01-24 |
| KR102675027B1 (ko) | 2024-06-14 |
| US20230025407A1 (en) | 2023-01-26 |
| CA3140043A1 (en) | 2020-11-19 |
| US20220110892A1 (en) | 2022-04-14 |
| US11571398B1 (en) | 2023-02-07 |
| IL288044A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102675027B1 (ko) | 에페드린 또는 에페드린 염을 포함하는 조성물 및 그의 제조 및 사용 방법 | |
| KR101632103B1 (ko) | 덱스메데토미딘 프레믹스 제형 | |
| AU2020314494B2 (en) | Stable AST-3424 injection preparation and preparation method | |
| HK40068558A (en) | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same | |
| AU2013202661B2 (en) | Dexmedetomidine premix formulation | |
| US12295932B2 (en) | Succinylcholine chloride prefilled syringe | |
| AU2013206421B2 (en) | Dexmedetomidine premix formulation | |
| WO2022018177A1 (en) | Suxamethonium composition and prefilled syringe thereof | |
| HK1185225B (en) | Dexmedetomidine premix formulation | |
| HK1185225A (en) | Dexmedetomidine premix formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20240610 Application number text: 1020217040545 Filing date: 20211210 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20240710 Comment text: Request for Examination of Application |